June 28, 2021
3 min watch
Save
VIDEO: Irreversible FLT3 inhibitor may have more permanent effect in AML
In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a new irreversible FLT3 inhibitor that was tested in a first-in-human study.
The phase 1 study, presented at ASCO21, evaluated an irreversible FMS-like tyrosine kinase 3 inhibitor in 52 patients with relapsed or refractory acute myeloid leukemia.
“The idea is that it has a more permanent effect on the protein made by the mutation, and it is even more selective. It will also work on subsequent mutations that happen in the tyrosine kinase domain,” Gerds said.
Published by:
Sources/Disclosures
Collapse
Source:
Lachowiez C.A. et al. Abstract 7012. Presented at: ASCO Annual Meeting (virtual meeting); 2021; June 4-8, 2021.
Disclosures:
Gerds reports no relevant financial disclosures.